Safety and preliminary activity results of the GATTO study, a phase Ib study combining the anti-TA-MUC1 antibody gatipotuzumab with the anti-EGFR tomuzotuximab in patients with refractory solid tumors

  1. Ochsenreither, S.
  2. Fiedler, W.M.
  3. Conte, G.D.
  4. Macchini, M.
  5. Matos, I.
  6. Habel, B.
  7. Ahrens-Fath, I.
  8. Raspagliesi, F.
  9. Lorusso, D.
  10. Keilholz, U.
  11. Rolling, C.
  12. Kebenko, M.
  13. Klinghammer, K.F.
  14. Saavedra, O.
  15. Baumeister, H.
  16. Zurlo, A.
  17. Garralda, E.
Journal:
ESMO Open

ISSN: 2059-7029

Year of publication: 2022

Volume: 7

Issue: 2

Type: Article

DOI: 10.1016/J.ESMOOP.2022.100447 GOOGLE SCHOLAR lock_openOpen access editor
Data source: Scopus